Our combined immunometric assay and Western blot analyses confirmed the presence of PIVKA-II in sera from patients with both cancer types and uncovered differential co-expression patterns with canonical EMT markers: Vimentin and E-cadherin [28,29]. The gene discussed is CDH1; the disease is cancer.